Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. - Wikidata - wikimedia - TriplyDB

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

http://www.wikidata.org/entity/Q34106883

about

Genomic landscape of megakaryopoiesis and platelet function defects Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Refractory anemia with ring sideroblasts and RARS with thrombocytosis Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?The European Hematology Association Roadmap for European Hematology Research: a consensus document Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.When cancer and immunology meet Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.Comprehensive Molecular Profiling of Archival Bone Marrow Trephines Using a Commercially Available Leukemia Panel and Semiconductor-Based Targeted Resequencing Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.miR-506 inhibits cell proliferation and invasion by targeting TET family in colorectal cancer.Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.The molecular pathogenesis of the myelodysplastic syndromes.Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Acute Myeloid Leukemia With Myelodysplasia-Related Changes.Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.CMML: Clinical and molecular aspects.Genomic determinants of chronic myelomonocytic leukemia.Panobinostat for the treatment of acute myelogenous leukemia.Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Improving Prognostic Modeling in Myelodysplastic Syndromes.Splicing factor gene mutations in hematologic malignancies.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

P2860

Q26770869-05754CAD-0CC9-4940-A8EC-09AB0F5B5599 Q26801573-3C0536B3-5884-47FF-B60C-383F8C3523FE Q28083238-DCA250D6-0E73-48E9-B40E-9502BE785E3B Q28387115-27C7005A-44BD-45F0-9681-195B2B5F0C04 Q28830861-B8E59260-E1B9-4DA8-BEB8-128ED73EDD0B Q30235355-A36B7F88-C59F-430C-AC46-8BC8ABE91214 Q30249108-4875E7D9-5B49-454B-BD94-860D208E2973 Q33427165-8C806A99-A0EA-40F3-BC0A-254788B55311 Q33435980-B592C9A3-32F4-463C-9698-281C0EACF460 Q34700714-C2682E38-97A6-4838-9239-2C0193D363A1 Q34729522-3D1E30C4-3471-4DDE-82EA-14AFD9109ACD Q35538419-7461B9DC-609B-482D-991C-7B86A00333F1 Q35722733-14650431-B461-4317-ADF8-A6C44C600366 Q35836896-A9D7D16B-559B-463B-8691-7D09CCECBFC6 Q35925679-4F98A605-6377-4A63-B298-4C5EA4307872 Q36054758-C2582D40-11B1-40EB-8450-7E14FFC70F47 Q36507980-E43844EA-472D-4308-83DA-1E7B18C3E274 Q36642726-16CDBB11-0593-4BF2-8B5C-4EA8B2541AC6 Q36805191-1AFC4454-3794-4516-8D1D-6C8D6C294A95 Q37327426-42E5A81F-D9D3-410E-8E6A-2A86D2DAAC22 Q37688233-623E3829-AF01-4A4D-BFD4-EB79760046AD Q37742267-6DEE9664-17E4-4D5C-A53F-EA4AB04F211D Q38248429-3FE1E996-B00C-4FA7-8B96-0C22434D86D1 Q38289057-5DEE3B3B-183A-4236-8D0A-100B1E6DD1F8 Q38341998-D9423B09-C1C2-4550-AC4C-8BD06BA33DC1 Q38363814-EA24118D-4E16-4E8E-8DC3-225CFB9AF902 Q38379074-96B790D3-38F3-47CD-BAF2-4E828095ADD7 Q38471249-9CAC9DAA-4A80-4D50-A1F7-DE926B5B6171 Q38526939-8EC8AFD5-4991-4118-A9EA-40A429DD065A Q38541690-BC460CD4-7F3C-4DFF-BF95-9031524FFF22 Q38570399-97F49C5C-9E16-4119-82E7-C96FF8934CF0 Q38644826-9CDA897D-94B1-4720-9991-147BD9E9C261 Q38687894-A5AD64BE-E407-41AA-8321-ACCF8EAA7F35 Q38689508-E1B23D32-4039-4B79-9344-3885575A093C Q38757999-FF12CA2E-843B-4E10-AD31-50E068F025A3 Q38835113-456F1EAE-4844-4D6F-98FD-13F408CFA601 Q38905610-16F3C57D-518A-4C2F-A99B-B87D4E549E6F Q38922020-48291736-602A-4EAD-B986-F0172078FA70 Q39035441-F8615F54-14CD-40D7-A97F-C69DD4470087 Q39048645-1A47EFF0-6177-42CD-9694-61551EF194E1

P2860

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

http://www.wikidata.org/entity/Q34106883

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@ast

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@en

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@nl

type

label

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@ast

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@en

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@nl

prefLabel

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@ast

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@en

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@nl

P1433

Q34106883-BE00C683-8A4C-4E5B-9B7C-13D2A947DEE3

P1476

Q34106883-1A1D6027-4B4D-450B-A8BE-E5AA24C65469

P2093

Q34106883-07844511-44B0-4280-83A8-964C9B20D2E0

Q34106883-1020D351-50E4-42DE-88CD-05BBDDDFAAFC

Q34106883-132D44B3-1746-46CF-AF3A-1CECEA214658

Q34106883-3EC5E58C-7D9B-4747-9010-7E5B85C0EC17

Q34106883-41A2162B-68B5-4702-93C8-9330B807FE1B

Q34106883-4372DBC3-04DA-4B77-9574-187CA2CE0E56

Q34106883-71144A49-6E00-4EF9-8B78-FDC9D73F1E90

Q34106883-7BDE6FC6-C82E-4042-893F-FABEBAC75724

Q34106883-7D810089-B79A-48D5-995B-EDE222C44A6C

Q34106883-8F5CFBFD-564D-4CB3-9F02-233F4A5C5EC0

P2860

Q34106883-0295CDBC-5C25-4C53-85BB-9E3E9D0C8429

Q34106883-0633BA2B-37F8-4BB3-871E-0E71234C9B7A

Q34106883-1A958E47-04E1-4D19-A94D-9779CDE64951

Q34106883-2BEBB494-EE10-4B90-88FC-44001E4D715C

Q34106883-4600DB90-B666-4F8E-95C6-58BD76602D72

Q34106883-479C0030-B4BA-463A-B6D2-FA712CB057BF

Q34106883-47B5E38B-14A9-4B29-99BD-6101F5E4A483

Q34106883-49DCE666-F222-4B47-859C-28CEF51D623E

Q34106883-4A5A1255-7066-48DC-BB4A-968A76D4EED8

Q34106883-4F74E78E-1C94-409E-99C0-2E6FE077E032

P304

Q34106883-BBC01CD6-9BA7-46A6-A079-3CA207851781

P31

Q34106883-34C15854-7113-4A2C-B5FD-7B55B43D2D40

P356

Q34106883-2B35BAEB-E8A6-42F3-A9B4-E04C0286D79C

P407

Q34106883-444DB9BB-6DE4-4A63-9920-75D7B5A6E544

P433

Q34106883-61F535CD-DFB3-4420-86DB-6E6AE5BFC3A5

P478

Q34106883-85A03F2A-5828-42F0-9D5A-A7299C6C33EA

P50

Q34106883-0151E2BF-EB1A-4BC0-A6F9-1DDCCC915DC4

Q34106883-1A91A611-6333-4C10-8EDA-4051B9A69600

P577

Q34106883-6757FC8E-B746-42D8-82A8-FA6F19F3B1AA

P5875

Q34106883-D1C647B6-F9D2-442F-A774-5CC6747C3EAD

P698

Q34106883-DB151491-BDD8-4317-A0E1-8A5DC6E2731F

P932

Q34106883-4BAE5CE2-D850-413E-99BF-0D0292E08601

P356

BLOOD-2014-03-560227

P1433

P1476

Driver somatic mutations ident ...... neoplasms with myelodysplasia.

@en

P2093

Angela Brisci

http://www.w3.org/2001/XMLSchema#string

Anna Gallì

http://www.w3.org/2001/XMLSchema#string

Chiara Elena

http://www.w3.org/2001/XMLSchema#string

Cristiana Pascutto

http://www.w3.org/2001/XMLSchema#string

Elisa Bono

http://www.w3.org/2001/XMLSchema#string

Emanuela Boveri

http://www.w3.org/2001/XMLSchema#string

Erica Travaglino

http://www.w3.org/2001/XMLSchema#string

Francesca Bruno

http://www.w3.org/2001/XMLSchema#string

Ilaria Ambaglio

http://www.w3.org/2001/XMLSchema#string

Laura Cremonesi

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

The World Health Organization (WHO) classification of the myeloid neoplasms

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

Frequent pathway mutations of splicing machinery in myelodysplasia

Mutation in TET2 in myeloid cancers

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

P304

1513-1521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-03-560227

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Elli Papaemmanuil

P577

2014-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263514374

http://www.w3.org/2001/XMLSchema#string

P698

24970933

http://www.w3.org/2001/XMLSchema#string

P932

4148773

http://www.w3.org/2001/XMLSchema#string